

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C12N 5/00</p>		A1	<p>(11) International Publication Number: WO 95/12664 (43) International Publication Date: 11 May 1995 (11.05.95)</p>
<p>(21) International Application Number: PCT/US94/11535 (22) International Filing Date: 12 October 1994 (12.10.94)</p>			<p>(81) Designated States: AU, CA, FI, JP, KP, KR, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>
<p>(30) Priority Data: 08/146,860 3 November 1993 (03.11.93) US</p>			<p>Published <i>With international search report.</i></p>
<p>(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).</p>			
<p>(72) Inventors: ADAMSON, S., Robert; 15 Cathy Road, Chelmsford, MA 01824 (US). DRAPEAU, Denis; 15 Norwood Road, Salem, NH 03079 (US). LUAN, Yen-Tung; 3 Armand Drive, Chelmsford, MA 01824 (US). MILLER, Douglas, Alan; 6 Alexander Avenue, Salem, NH 03079 (US).</p>			
<p>(74) Agent: LAZAR, Steven, R.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).</p>			
<p>(54) Title: ADAPTION OF MAMMALIAN CELL LINES TO HIGH CELL DENSITIES</p>			
<p>(57) Abstract</p> <p>Methods and nutrient media are disclosed useful for adapting mammalian cell lines to culture at increased cell densities.</p>			

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## ADAPTION OF MAMMALIAN CELL LINES TO HIGH CELL DENSITIES

5

### FIELD OF THE INVENTION

The present invention relates to improved methods of expressing proteins through culture  
10 of mammalian cell lines. In particular, the present invention relates to methods of improving  
the productivity of mammalian cell lines through adaption to otherwise growth-limiting  
conditions.

### BACKGROUND OF THE INVENTION

It is known that various factors may be responsible for limiting the growth of cells at  
15 high cell densities. These factors include absence of sufficient amounts of nutrients needed by  
the cells for sustained growth, as well as the presence of growth-limiting concentrations of  
inhibitors that may be secreted by the cells in culture. One inhibitor that is secreted by  
mammalian cells is ammonia. See Miller et al., Bioprocess Engineering, 3:113-122 (1988);  
Inlow et al., United States Patent 5,156,964 describes a method for generating tolerance to  
20 ammonia that involves culturing cells in a medium to which ammonia has been added.  
Similarly, Schumpp et al., Cytotechnology, 8:39-44 (1992) describe a method for generating cell  
lines tolerant of both ammonia and lactic acid by culturing cells in a medium to which both  
ammonia and lactic acid had been added.

The previous methods have several drawbacks. First, in order to generate tolerance to  
25 an inhibitor according to the above methods, it is first necessary to determine that a particular  
inhibitor is a growth-limiting factor for cells and then to develop a protocol for generating  
tolerance to that inhibitor. Second, the growth of cell lines which are generated with tolerance  
to a particular inhibitor according to the above methods may then be limited by a second,  
different inhibitor. Repeated experiments may be necessary to generate tolerance to multiple  
30 growth-limiting inhibitors in order to achieve significant increases in cell densities.

## SUMMARY OF THE INVENTION

According to the present invention, many of the drawbacks of the above prior art are overcome. The present invention provides methods by which the growth-limiting factors present for a particular cell line can be overcome without first conducting time-consuming testing to identify the specific growth-limiting inhibitors.

It is one object of the present invention to provide methods of improving the productivity of mammalian cell lines.

It is another object of the present invention to provide methods for adapting cell lines to high cell densities.

It is yet another object of the present invention to provide nutrient-rich growth media in which nutrients are present in sufficient quantity so that they are not expected to limit cell growth.

According to the present invention, the above objects are largely achieved by providing methods for adapting mammalian cell lines to culture at increased cell densities. The methods of the present invention comprise adapting mammalian cell lines to grow at increased cell densities, by (a) initiating a passage by diluting a culture containing mammalian cells with a suitable growth medium by a dilution factor suitable for the passage duration; (b) maintaining pH, dissolved oxygen, and nutrients at non-limiting levels during the passage; and repeating steps (a) and (b) at least about 5 times. In a preferred embodiment of the invention, the steps are repeated about 5 to about 20 times.

The present invention further comprises methods for adapting CHO cell lines to grow to increased cell densities, comprising:

a) initiating a passage of duration approximately 1 to 5 days by diluting a culture containing CHO cells at a density of at least approximately  $1 \times 10^6$  cells/ml with a suitable growth medium, the dilution factor being suitable to the passage duration; (b) maintaining pH, dissolved oxygen, and nutrients in non-limiting levels during the passage; and (c) repeating steps (a) and (b) at least about 5 times.

The present invention further comprises methods for adapting CHO cell lines to grow to increased cell densities comprising: (a) initiating a passage of duration approximately 3 to 4 days by diluting a culture containing CHO cells at a density of at least approximately  $1 \times 10^6$  cells/ml with a suitable growth medium, the dilution factor being suitable to the passage duration; (b)

maintaining pH, dissolved oxygen, and nutrients at non-limiting levels during the passage; and (c) repeating steps (a) and (b) at least about 5 times.

In a preferred embodiment, the present invention comprises a method for adapting mammalian cell lines to culture at increased cell densities, said method comprising continuously or periodically diluting a cell culture, containing mammalian cells, with a suitable growth medium, for between approximately 10 and 60 days, while maintaining pH, dissolved oxygen and nutrients at non-limiting levels.

Other preferred methods of the present invention comprise adapting CHO cell lines to culture at increased cell densities, said method comprising continuously or periodically diluting a culture containing CHO cells, at a density of at least approximately  $1 \times 10^6$  cells/ml with a suitable growth medium, the dilution rate being less than approximately  $0.029 \text{ hr}^{-1}$ , while maintaining pH, dissolved oxygen and nutrients at non-limiting levels. Preferred dilution rates are between approximately  $0.018\text{hr}^{-1}$  and  $0.026\text{hr}^{-1}$ .

#### DETAILED DESCRIPTION OF THE INVENTION

Mammalian cell lines are used for the production of commercially useful proteins. Some mammalian cell lines which are commonly used include chinese hamster ovary (CHO) cell lines, hybridomas, monkey COS-1 cells, HeLa cells, melanoma cell lines such as the Bowes cell line, hybridoma cell lines, mouse L cells, mouse fibroblasts, mouse NIH 3T3 cells and the CV-1 cell line. In the present invention, these and other mammalian cell lines may be adapted for culture at high cell densities.

Suitable growth media for the present invention include any medium which provides nutrients at non-limiting levels. Nutrients will generally be at non-limiting levels if raising concentrations of all nutrients results in no increase in growth rate. Nutrient concentrations may be maintained at non-limiting levels by either providing excess amounts of all nutrients in the fresh medium or by adding nutrients to the culture as they are taken up by the cells or degraded. A suitable growth medium for mammalian cell lines is disclosed in Ling et al., Experimental Cell Research; 52:469-489 (1968). Accordingly, one preferred growth medium contains the amino acid nutrients in the concentrations disclosed in Table 1.

TABLE 1

	Column I	Column II	Column III
	NUTRIENT	CONCENTRATION RANGE (MG/L)	OPTIMAL CONCENTRATION (MG/L)
5	L-asparagine H <sub>2</sub> O	30-360	540
	L-aspartic acid	69-798	266
	Glycine	30-450	60
	L-isoleucine	79-948	472
	L-leucine	158-1890	681
10	L-lysine HCl	229-2742	728
	L-methionine	75-894	238
	L-serine	79-948	630
	L-threonine	90-1074	381
	L-tryptophan	31-366	131
	L-tyrosine 2Na 2H <sub>2</sub> O	65-783	418
15	L-valine	141-1686	374

Other nutrients which may be added to the medium include inorganic salts, such as chlorides, phosphates, sulfates and nitrates, sugars, vitamins, and additives such as glutamine, pyruvate, linoleic, thioctic, selenite, hydrocortisone, insulin.

Other preferred growth media suitable for mammalian cell lines include a medium containing the components described in Table 2 below.

TABLE 2  
NUTRIENT COMPOSITION OF MEDIUM

	Column I	Column II	Column III	Column IV
	Components	Medium proposed by Ling et al. (mg/L) (1968)	Medium used for adaptation in Example (mg/L)	Preferred non-limiting medium (mg/L)
5	sodium chloride	7000	4600	4400
	potassium chloride	375	624	310
	calcium chloride, anhydrous	156	232	58
	sodium phosphate, dibasic, anhydrous		142	
	sodium phosphate, monobasic, hydrate		125	130
10	magnesium chloride, anhydrous		57	
	magnesium sulfate, anhydrous	120	98	84
	cupric sulfate, anhydrous	185	0.0016	0.0018
	ferrous sulfate, anhydrous		0.68	0.91
	ferric nitrate, nonahydrate	1.2	0.10	
15	zinc sulfate, septahydrate	0.86	0.86	0.92
	sodium selenite		0.010	0.010
	sodium bicarbonate		2440	2400
	L-alanine	45-534	36	71
	L-arginine	218-2616	600	760
20	L-asparagine hydrate	30-360	180	540
	L-aspartic acid	67-798	133	270
	L-cysteine hydrochloride hydrate		282	700
	L-cystine dihydrochloride	23-281	125	
	L-glutamic acid	103-1236	59	120
25	L-glutamine	212-2544	1168	1200

Components	Medium proposed by Ling et al. (mg/L) (1968)	Medium used for adaptation in Example (mg/L)	Preferred non-limiting medium (mg/L)
glycine	38-450	60	60
L-histidine hydrochloride hydrate	105-1260	126	290
L-isoleucine	79-948	210	470
L-leucine	158-1890	260	680
5 L-lysine hydrochloride	229-2742	291	730
L-methionine	75-894	104	240
L-phenylalanine	99-1188	165	330
L-proline	86-1032	138	280
L-serine	79-948	315	630
10 L-threonine	90-1074	190	380
L-tryptophan	31-366	33	130
L-tryosine disodium dihydrate	57-678	262	420
L-valine	141-1686	187	370
biotin	0.03	0.41	1.6
15 D-calcium pantothenate	5.0	4.5	18
choline chloride	350	18	72
folic acid	0.10	5.3	21
i-inositol	35	25	100
nicotinamide	20	4.0	16
20 pyridoxine hydrochloride		0.062	16
pyridoxal hydrochloride	2.5	4.0	
riboflavin	1.5	0.44	1.8
thiamine hydrochloride	1.0	4.3	18
vitamin B12	0.003	1.6	5.6

Components	Medium proposed by Ling et al. (mg/L) (1968)	Medium used for adaptation in Example (mg/L)	Preferred non-limiting medium (mg/L)
D-glucose	2000	6000	6200
sodium pyruvate		110	
linoleic acid	0.21	0.084	0.17
thioctic acid	0.70	0.21	0.42
putrescine dihydrochloride		2.2	2.0
polyvinyl alcohol		2400	2400
insulin or Nucellin	1.0	10	10
hydrocortisone		0.072	0.072
methotrexate		1.3	
soybean phospholipid		10	
fetal bovine serum		5000	
B-glycerophosphate, disodium	1000		
D-sorbitol	100		
oxalacetic acid	65		
thymidine	10		
deoxycytidine	11		
homocysteine thiolactate	8-90		
glutathione, reduced	31-372		
sodium molybdate, dihydrate	0.015		
vitamin A acetate	1.0		
vitamin D3	0.005		
$\alpha$ -tocopherol	7.0		
oleic acid	0.2		
arachidonate, methyl	0.02		

Components	Medium proposed by Ling et al. (mg/L) (1968)	Medium used for adaptation in Example (mg/L)	Preferred non-limiting medium (mg/L)
cholesterol	5		
ovo-lecithin	25		
ethanol	2000		

5 Suitable dilution factors (for passaging) and suitable dilution rates (for continuous culture) appropriate for adapting a particular mammalian cell line to grow to increased cell densities may be calculated using the formulas:

$$\text{dilution factor} = e^{\mu t}$$

10

$$\text{dilution rate} = \mu$$

where  $t$  is the duration in hours of the upcoming passage and  $\mu$  is any quantity less than  $\mu_{\max}$ , preferably a quantity between approximately  $(0.6 \times \mu_{\max})$  and approximately  $(0.9 \times \mu_{\max})$ .  $\mu_{\max}$  in hour<sup>-1</sup>, is the specific growth rate of the cell line when none of the following extracellular factors limits growth: pH, dissolved oxygen, nutrient depletion and cell-generated inhibitors.

15 The magnitude of  $\mu_{\max}$  may be estimated without precise measurement in a variety of ways. For example, an estimate of  $\mu_{\max}$  may be generated as follows. First the maximum cell density attainable in a spinner flask using a common medium (such as a 1:1 mixture of DME and F12) is determined by suspending growth phase cells in this medium in the spinner flask and measuring the cell density on each subsequent day until cell density no longer rises. Next, 20 growth phase cells are suspended in fresh medium in another spinner flask at a starting density approximately 10-fold below the maximum attainable density and cultured for approximately 2 days. This culture is diluted with fresh medium to the same starting cell density every two days for several passages. The estimate of  $\mu_{\max}$  is the growth rate observed during these passages, 25 calculated using the following formula:

$$\mu_{\max} = (\ln X_f - \ln X_i)/t$$

where  $X_f$  is the cell density at the end of a typical passage,  $X_i$  is the cell density at the beginning

of the same passage, and  $t$  is the duration of the passage in hours.

For CHO cell lines, a suitable dilution factor for a given duration of passage may be as follows: If the passage is approximately 1 day, a suitable dilution factor is less than about 2, preferably from about 1.5 to about 2. If the passage duration is approximately 2 days, a suitable dilution factor is less than about 4, preferably from about 2 to about 4. If the passage duration is approximately 3 days, a suitable dilution factor is less than about 8, preferably from about 3 to about 7. If the passage duration is approximately 4 days, suitable dilution factors are less than about 16, preferably from about 5 to about 13. If the passage duration is approximately 5 days, a suitable dilution factor is less than about 32, preferably from about 9 to about 23.

5 For other mammalian cell lines, suitable dilution factors may be calculated on the basis of the maximum growth rate of the cell line. The maximum growth rate for a cell line may be determined as described above.

10

In the method of the present invention, relatively constant levels of pH, dissolved oxygen, and nutrients are maintained at non-limiting levels during the passage. This may preferably be accomplished by performing the adaption process in a bioreactor. pH may be maintained at the proper pH by addition of a suitable alkaline or acidic additive or buffer, for example sodium carbonate and sodium bicarbonate. Dissolved oxygen may be maintained by introduction of oxygen or air bubbles. If necessary, nutrient levels may be maintained by the addition of those nutrients which are depleted, or by addition of fresh growth medium.

15

20 In the present invention, mammalian cell lines, such as CHO cell lines, may be cultured at a suitable cell density, which may be approximately  $1 \times 10^6$  cells/ml, in a suitable growth medium, and may be diluted in accordance with the above description.

25 The present invention is illustrated by the following examples. These examples do not limit the invention in any manner. It is contemplated that minor improvements and variations may be made which are part of the present invention.

#### EXAMPLES

30 The recombinant chinese hamster ovary cell (CHO) line E5F3G expresses recombinant human M-CSF, as described in Clark et al., United States Patents 4,868,119 and 4,879,227. As described below, the E5F3G cell line was adapted to grow to increased cell densities, and thereby generate higher concentrations of rhM-CSF.

E5F3G cells from a spinner flask were grown to a density of  $1.24 \times 10^6$  cells/ml in approximately 1000 ml of a nutrient-rich medium (Table 2) in a 2-L bioreactor (passage 1 in Table 3).

These cells were then cultured for an additional ten 3-day or 4-day passages in the 2-L bioreactor (passages 2 through 11) in the nutrient-rich medium. During each passage, pH was maintained at between 7.0 and 7.2 by addition of sodium carbonate and sodium bicarbonate and dissolved oxygen was maintained at between 20% and 60% of air saturation by introduction of oxygen bubbles. Each 3-day passage was started by diluting the culture from the preceding passage by a factor between 5.1 and 6.3, while each 4-day passage was started by diluting the culture from the preceding passage by a factor between 6.0 and 14.3.

The beneficial effect on the cell line was evident during two subsequent passages (passages 12 and 13). For example, in passage 12, which was started at a density of  $0.50 \times 10^6$  cells/ml, cell density reached  $4.90 \times 10^6$  cells/ml, and rhM-CSF titer reached 32.6 ug/ml. In contrast, in passage 4, which had been started at a higher cell density ( $0.59 \times 10^6$  cells/ml), cell density had reached only  $2.44 \times 10^6$  cells/ml and rhM-CSF titer had reached only 14.9 ug/ml.

Table 3: Adaptation of E5F3G cell line to increased cell densities

Passage number	Passage length (days)	Dilution ratio	Initial density (10 <sup>6</sup> /ml)	Final density (10 <sup>6</sup> /ml)	Final titer (ug/ml)
5	1	4	-	0.12	1.24
5	2	3	5.4	0.23	1.96
5	3	3	6.3	0.31	3.00
5	4	3	5.1	0.59	2.44
10	5	4	12.2	0.20	1.79
10	6	4	6.0	0.30	3.50
10	7	3	5.0	0.70	2.25
10	8	3	5.2	0.43	2.70
10	9	4	12.3	0.22	4.30
10	10	4	14.3	0.30	5.90
15	11	3	5.9	1.00	5.70
15	12	3	11.4	0.50	4.90
15	13	4	16.3	0.30	5.30
					34.2

## CLAIMS

We claim:

1. A method for adapting mammalian cell lines to grow at increased cell densities, said method comprising:

5 a) initiating a passage by diluting a culture containing mammalian cells with a suitable growth medium, the dilution factor being suitable for the passage duration;

b) maintaining pH, dissolved oxygen, and nutrients at non-limiting levels during the passage; and

c) repeating steps (a) and (b) at least about 5 times.

10

2. The method of claim 1, wherein steps (a) and (b) are repeated about 5 to about 20 times.

3. A method for adapting CHO cell lines to grow to increased cell densities, said method comprising:

15 a) initiating a passage of duration approximately 1 to 5 days by diluting a culture containing CHO cells at a density of at least approximately  $1 \times 10^6$  cells/ml with a suitable growth medium, the dilution factor being suitable for the passage duration;

b) maintaining pH, dissolved oxygen, and nutrients in non-limiting levels during the passage; and

20

c) repeating steps (a) and (b) at least about 5 times.

4. The method of claim 3, wherein steps (a) and (b) are repeated about 5 to about 20 times.

25

5. A method for adapting CHO cell lines to grow to increased cell densities, said method comprising:

a) initiating a passage of duration approximately 3 to 4 days by diluting a culture containing CHO cells at a density of at least approximately  $1 \times 10^6$  cells/ml with a suitable growth medium, the dilution factor being suitable to the passage duration;

30

b) maintaining pH, dissolved oxygen, and nutrients at non-limiting levels during the

passage; and

c) repeating steps (a) and (b) at least about 5 times.

6. The method of claim 5, wherein steps (a) and (b) are repeated about 5 to about 20 times.

5 7. A method for adapting mammalian cell lines to culture at increased cell densities, said method comprising continuously or periodically diluting a cell culture, containing mammalian cells, with a suitable growth medium, for between approximately 10 and 60 days, while maintaining pH, dissolved oxygen and nutrients at non-limiting levels.

10 8. A method for adapting CHO cell lines to culture at increased cell densities, said method comprising continuously or periodically diluting a culture containing CHO cells, at a density of at least approximately  $1 \times 10^6$  cells/ml with a suitable growth medium, the dilution rate being less than approximately  $0.029 \text{ hr}^{-1}$ , while maintaining pH, dissolved oxygen and nutrients at non-limiting levels.

15 9. The method of claim 8, wherein the dilution rate is between approximately  $0.018 \text{ hr}^{-1}$  and  $0.026 \text{ hr}^{-1}$ .

20 10. A medium according to claim 10, wherein the nutrients are present in the following concentrations: L-asparagine  $\text{H}_2\text{O}$ , about 540 mg/l; L-aspartic acid, about 266 mg/l; glycine, about 60 mg/l; L-isoleucine, about 472 mg/l; L-leucine, about 681 mg/l; L-lysine HCl, about 728 mg/l; L-methionine, about 238 mg/l; L-serine, about 630 mg/l; L-threonine, about 381 mg/l; L-tryptophan, about 131 mg/l; L-tyrosine  $2\text{Na}2\text{H}_2\text{O}$ , about 418 mg/l; L-valine, about 374 mg/l.

11. A medium suitable for the culture of mammalian cells at high cell densities, comprising components in the concentrations disclosed at columns III or IV of Table 2.

**INTERNATIONAL SEARCH REPORT**

Int. Appl. No  
PCT/US 94/11535

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12N/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,3 850 748 (COOK, R.A.) 1974 see the whole document ---	1
X	GB,A,2 251 249 (MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE) 1992 see page 8 ---	10
A	US,A,5 122 469 (MATHER, J.P.) 1992 see the whole document ---	1-11
A	US,A,5 156 964 (INLOW, D:) 1992 cited in the application see the whole document ---	1-11
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

'A' document defining the general state of the art which is not considered to be of particular relevance  
'E' earlier document but published on or after the international filing date  
'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
'O' document referring to an oral disclosure, use, exhibition or other means  
'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
'&' document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

6 February 1995

22 -02- 1995

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax (+31-70) 340-3016

Authorized officer

Fernandez y Branas, F

## INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/US 94/11535

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EXPERIMENTAL CELL RESEARCH, vol.52, 1968, NEW YORK pages 469 - 489 LING C.T. ET AL 'Chemically characterised concentrated corodies for continuous cell culture (the 7C'S culture media)' cited in the application see the whole document ---	1-11
A	R. IAN FRESHNEY 'Culture of Animal cells' 1987 , ALAN R. LISS, INC. , NEW YORK see page 127 - page 136 -----	1-11

1

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 94/11535

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-3850748	26-11-74	NONE		
GB-A-2251249	01-07-92	FR-A-	2671098	03-07-92
US-A-5122469	16-06-92	NONE		
US-A-5156964	20-10-92	NONE		

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**